Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: Current status and future research direction

Frontiers of Medicine in China

Volumn 5, Issue 1, 2011, Pages 45-52

  Hu, Jiong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute promyelocytic leukemia; Alltrans retinoic acid; Arsenic; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC; RETINOIC ACID;

HUMAN; PROMYELOCYTIC LEUKEMIA; REVIEW; SURVIVAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENIC; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; SURVIVAL ANALYSIS; TRETINOIN;

EID: 80055070370     PISSN: 16737342     EISSN: 16737458     Source Type: Journal    
DOI: 10.1007/s11684-011-0117-y     Document Type: Review

References (50)

1. Rowley J D, Golomb H M, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet, 1977, 1(8010): 549-550
2. Rousselot P, Hardas B, Patel A, Guidez F, Gäken J, Castaigne S, Dejean A, de Thé H, Degos L, Farzaneh F, et al. The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene, 1994, 9(2): 545-551
3. Wang Z Y, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 2008, 111(5): 2505-2515
4. Huang M E, Ye Y C, Chen S R, Chai J R, Lu J X, Zhoa L, Gu L J, Wang Z Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 1988, 72(2): 567-572
5. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood, 1990, 75(11): 2112-2117
6. Sanz M A, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, Bolufer P, Barragán E, Terol M J, González J D, Colomer D, Chillón C, Rivas C, Gómez T, Ribera J M, Bornstein R, Román J, Calasanz M J, Arias J, Alvarez C, Ramos F, Debén G. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood, 1999, 94(9): 3015-3021
7. Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Adès L. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol, 2009, 27(16): 2668-2676
8. Tallman M S, Altman J K. How I treat acute promyelocytic leukemia. Blood, 2009, 114(25): 5126-5135
9. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997, 89(9): 3354-3360
10. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood, 1996, 88(3): 1052-1061
11. Niu C, Yan H, Yu T, Sun H P, Liu J X, Li X S, Wu W, Zhang F Q, Chen Y, Zhou L, Li J M, Zeng X Y, Yang R R, Yuan M M, Ren M Y, Gu F Y, Cao Q, Gu B W, Su X Y, Chen G Q, Xiong S M, Zhang T D, Waxman S, Wang Z Y, Chen Z, Hu J, Shen Z X, Chen S J. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 1999, 94(10): 3315-3324
12. Soignet S L, Frankel S R, Douer D, Tallman M S, Kantarjian H, Calleja E, Stone R M, Kalaycio M, Scheinberg D A, Steinherz P, Sievers E L, Coutré S, Dahlberg S, Ellison R, Warrell R P Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol, 2001, 19(18): 3852-3860
13. Mathews V, George B, Lakshmi K M, Viswabandya A, Bajel A, Balasubramanian P, Shaji R V, Srivastava V M, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood, 2006, 107(7): 2627-2632
14. Mathews V, George B, Chendamarai E, Lakshmi K M, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji R V, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol, 2010, 28(24): 3866-3871
15. Ghavamzadeh A, Alimoghaddam K, Ghaffari S H, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol, 2006, 17(1): 131-134
16. Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y, Li X, Han X, Zhou J, Liu P. Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide-an analysis of 242 cases. Chin J Hematol, 2000, 21(2): 67-70
17. Zhou G B, Zhang J, Wang Z Y, Chen S J, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci, 2007, 362(1482): 959-971
18. Lallemand-Breitenbach V, Guillemin M C, Janin A, Daniel M T, Degos L, Kogan S C, Bishop J M, de Thé H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med, 1999, 189(7): 1043-1052
19. Jing Y, Wang L, Xia L, Chen G Q, Chen Z, Miller WH, Waxman S. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood, 2001, 97(1): 264-269
20. Raffoux E, Rousselot P, Poupon J, Daniel M T, Cassinat B, Delarue R, Taksin A L, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand J P, de Thé H, Degos L, Hermine O, Dombret H. Combined treatment with arsenic trioxide and all-transretinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol, 2003, 21(12): 2326-2334
21. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA, 2004, 101(15): 5328-5335
22. Hu J, Liu Y F, Wu C F, Xu F, Shen Z X, Zhu Y M, Li J M, Tang W, Zhao WL, Wu W, Sun H P, Chen Q S, Chen B, Zhou G B, Zelent A, Waxman S, Wang Z Y, Chen S J, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA, 2009, 106(9): 3342-3347
23. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood, 2006, 107(9): 3469-3473
24. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol, 2009, 27(4): 504-510
25. Powell B L, Moser B, Stock W, Gallagher R E, Willman C L, Stone R M, Rowe J M, Coutre S, Feusner J H, Gregory J, Couban S, Appelbaum F R, Tallman M S, Larson R A. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 2010, 116(19): 3751-3757
26. Sanz M A, Grimwade D, Tallman M S, Lowenberg B, Fenaux P, Estey E H, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett A K, Lo-Coco F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2009, 113(9): 1875-1891
27. Zhu J, Lallemand-Breitenbach V, de Thé H. Pathways of retinoic acid-or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene, 2001, 20(49): 7257-7265
28. Zhu J, Zhou J, Peres L, Riaucoux F, Honoré N, Kogan S, de Thé H. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell, 2005, 7(2): 143-153
29. 3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med, 2001, 193(12): 1361-1371
30. Zhang X W, Yan X J, Zhou Z R, Yang F F, Wu Z Y, Sun H B, Liang W X, Song A X, Lallemand-Breitenbach V, Jeanne M, Zhang Q Y, Yang H Y, Huang Q H, Zhou G B, Tong J H, Zhang Y, Wu J H, Hu H Y, de Thé H, Chen S J, Chen Z. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 2010, 328(5975): 240-243
31. Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de Thé H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res, 2009, 15(20): 6321-6326
32. Wang J C, Dick J E. Cancer stem cells: lessons from leukemia. Trends Cell Biol, 2005, 15(9): 494-501
33. Grignani F, Ferrucci P F, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell, 1993, 74(3): 423-431
34. Du C, Redner R L, Cooke M P, Lavau C. Overexpression of wildtype retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes. Blood, 1999, 94(2): 793-802
35. Nasr R, Guillemin M C, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi P P, Rochette-Egly C, Zhu J, de Thé H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med, 2008, 14(12): 1333-1342
36. Delva L, Cornic M, Balitrand N, Guidez F, Micléa J M, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L, et al. Resistance to alltrans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood, 1993, 82(7): 2175-2181
37. Zheng X, Seshire A, Rüster B, Bug G, Beissert T, Puccetti E, Hoelzer D, Henschler R, Ruthardt M. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/ RARalpha-positive leukemic stem cells. Haematologica, 2007, 92(3): 323-331
38. Kogan S C. Curing APL: differentiation or destruction? Cancer Cell, 2009, 15(1): 7-8
39. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan D E, Teruya-Feldstein J, Pandolfi P P. PML targeting eradicates quiescent leukaemia-initiating cells. Nature, 2008, 453(7198): 1072-1078
40. Luesink M, Pennings J L, Wissink W M, Linssen P C, Muus P, Pfundt R, deWitte T J, van der Reijden B A, Jansen J H. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood, 2009, 114(27): 5512-5521
41. Tallman MS, Andersen J W, Schiffer C A, Appelbaum F R, Feusner J H, Ogden A, Shepherd L, Rowe J M, François C, Larson R S, Wiernik P H. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood, 2000, 95(1): 90-95
42. Ng J C, Wang J, Shraim A. A global health problem caused by arsenic from natural sources. Chemosphere, 2003, 52(9): 1353-1359
43. Ficker E, Kuryshev Y A, Dennis A T, Obejero-Paz C, Wang L, Hawryluk P, Wible B A, Brown A M. Mechanisms of arsenicinduced prolongation of cardiac repolarization. Mol Pharmacol, 2004, 66(1): 33-44
44. Kojima C, Ramirez D C, Tokar E J, Himeno S, Drobná Z, Stýblo M, Mason R P, Waalkes M P. Requirement of arsenic biomethylation for oxidative DNA damage. J Natl Cancer Inst, 2009, 101(24): 1670-1681
45. Hughes M F. Arsenic methylation, oxidative stress and cancer-is there a link? J Natl Cancer Inst, 2009, 101(24): 1660-1661
46. Lu D P, Qiu J Y, Jiang B, Wang Q, Liu K Y, Liu Y R, Chen S S. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood, 2002, 99(9): 3136-3143
47. The Cooperation Group of Phase II Clinical Trial of Compound Huangdai Tablet. Phase II clinical trial of compound Huangdai tablet in newly diagnosed acute promyelocytic leukemia. Chin J Hematol, 2006, 27(12): 801-804
48. Sun F, Chen N N, Cheng Y B. Compound realgar and natural indigo tablets in treatment of acute promyelocytic leukemia: a summary of experience in 204 cases. Zhong Xi Yi Jie He Xue Bao, 2008, 6(6): 639-642
49. Au W Y, Kumana C R, Kou M, Mak R, Chan G C, Lam C W, Kwong Y L. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood, 2003, 102(1): 407-408
50. Siu C W, Au WY, Yung C, Kumana C R, Lau C P, Kwong Y L, Tse H F. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for longterm cardiac safety. Blood, 2006, 108(1): 103-106